Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)

Table 2 Sources and estimation of raw utility scores^a

	Value	Source
Baseline utility value for age 60	0.84	Ara and Brazier [32]
Sexual dysfunction	0.89	Stewart et al. [37]
Sexual dysfunction and urinary incontinence	0.78
Impotence and bowel dysfunction	0.57
Impotence, urinary incontinence, and bowel dysfunction	0.45
Local disease progression	0.67
Metastatic cancer	0.25
Active monitoring	0.98	Authors’ assumption

^aThe table reports ‘raw’ scores. The final scores used in our calculations were obtained by combining the baseline score with these raw scores using a multiplicative model. For instance, the final score for sexual dysfunction is obtained by multiplying the score in Stewart et al. by our baseline utility value (see the Additional file 1)
Finally, for patients alive without BCR, the utility scores were estimated at 0.79 under AM, 0.76 under RP and 0.72 under RHT. By merging the utilities related to the combined event (disease progression or death), the expected utility scores after the treatment failure were assessed at 0.34 under AM, 0.24 under RP and 0.20 under RHT. A sensitivity analysis was carried out by varying the patient age between 55 and 75 years. The conclusions of the analyses were unchanged (data not shown)

ISSN: 1472-6947